article thumbnail

High biologics demand spurs need for greater contract manufacturing

Pharmaceutical Technology

“Biologics products may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system.

article thumbnail

Outlook on the Biologics Contract Manufacturing Global Market to 2031 – Focus on Monoclonal Antibodies, Recombinant Proteins, Vaccines and Molecular Therapy – ResearchAndMarkets.com

BioTech 365

Outlook on the Biologics Contract Manufacturing Global Market to 2031 – Focus on Monoclonal Antibodies, Recombinant Proteins, Vaccines and Molecular Therapy – ResearchAndMarkets.com Outlook on the Biologics Contract Manufacturing Global Market to 2031 – Focus on Monoclonal Antibodies, Recombinant Proteins, … Continue reading (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biopharmaceutical Contract Manufacturing: Transforming Promise into Reality

Roots Analysis

In this context, it is worth highlighting those 14 biopharmaceutical products ( including cell therapies, gene therapies, monoclonal antibodies and recombinant proteins ) were approved in the US alone, in 2021. As a result, biopharmaceutical contract manufacturing has picked up pace in the recent years.

article thumbnail

Biopharmaceutical Contract Manufacturing: Transforming Promise into Reality

Roots Analysis

In this context, it is worth highlighting those 14 biopharmaceutical products ( including cell therapies, gene therapies, monoclonal antibodies and recombinant proteins ) were approved in the US alone, in 2021. As a result, biopharmaceutical contract manufacturing has picked up pace in the recent years.

article thumbnail

Biologics Contract Manufacturing – Current Interest of the Pharmaceutical Industry

Roots Analysis

Although biopharmaceuticals offer significant profit margins and have demonstrated the potential to treat a myriad of disease indications, they are generally associated with high costs of development and complex manufacturing protocols. Advanced and complex technologies are required for manufacturing, as well as testing of biopharmaceuticals.

article thumbnail

Growing Demand for Oligonucleotides Proposes Shedload of Opportunities for Contract Manufacturers

Roots Analysis

In the 20 th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. These contract service providers are actively entering into strategic collaborations to augment their existing portfolios.

article thumbnail

Pfizer signs deal with Gilead to manufacture COVID-19 antiviral remdesivir

pharmaphorum

Under the terms of the agreement Pfizer will become one of several external partners who manufacture the investigational treatment for the disease. Pfizer will provide contract manufacturing services at its facility in McPherson, Kansas, to supply the drug to Gilead.